MedPath

Celecoxib in Postoperative Analgesia for Radius Fracture Surgery

Phase 4
Completed
Conditions
Pain, Postoperative
Interventions
Registration Number
NCT05288374
Lead Sponsor
Charles University, Czech Republic
Brief Summary

Patients scheduled for elective osteosynthesis of the distal radius will be randomized to receive celecoxib 100 mg orally (PO) at 6 in the morning before surgery and every 12 hours for 2 days thereafter, or a placebo pill in the same regimen. After surgery under general anaesthesia, they will receive paracetamol 1 g intravenously (IV) every 6 hours and if pain intensity is greater than 4 on a numeric rating scale (NRS) of 0-10, piritramid 15 mg intramuscularly (IM) will be administered. Pain intensity, piritramid consumption and side effects of treatment will be recorded in a questionnaire for 2 days.

Detailed Description

A prospective single-blinded randomized study will be performed in patients of the Orthopaedic Clinic of the 3rd Medical Faculty of Charles University (3LF UK) and the Faculty Hospital Kralovske Vinohrady (FHKV) scheduled for elective osteosynthesis of the distal radius. The expected number of participants is 25 in each arm of the study. They will be randomized by envelope method into an non-steroidal analgesic (NSA) group, which will receive celecoxib at 6 in the morning before surgery, and a C group, which will receive a placebo pill prepared by the hospital pharmacy. General anesthesia will be performed in both groups in the standard way using propofol, sufentanil and sevoflurane 1 minimal alveolar concentration (MAC) with air and oxygen at 40% concentration. At the end of surgery, each patient will be given paracetamol 1 g intravenously (IV) and ondansetron 4 mg IV. Pain intensity after surgery will be measured on a numerical rating scale (NRS) 0-10. For postoperative analgesia, both groups will receive paracetamol 1 g IV. every 6 hours, and for NRS\>4 pain intensity, piritramid 15 mg intramuscularly (IM). The NSA group will receive celecoxib 100 mg orally (PO) at 6 in the morning and 6 in the afternoon, and group C will receive placebo at the same interval.

Parameters to be monitored will be postoperative pain intensity for the primary objective, and opioid piritramid consumption and side effects of the treatment for the secondary objectives. NRS, number of doses of piritramid and side effects will be recorded in a coded questionnaire.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
42
Inclusion Criteria
  • Patients scheduled for osteosynthesis of distal radius fracture
Exclusion Criteria
  • Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to celecoxib
  • History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs.
  • Patients who have demonstrated allergic-type reactions to sulfonamides.
  • Inability to understand the questionnaire

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PlaceboPlaceboA placebo pill provided by a hospital pharmacy will be administered in the day of surgery at 6 in the morning and 6 in the afternoon for 3 days.
CelecoxibCelecoxib 100 mgCelecoxib 100 mg orally will be administered in the day of surgery at 6 in the morning and will be continued regularly at 6 in the morning and 6 in the afternoon for 3 days.
Primary Outcome Measures
NameTimeMethod
Postoperative pain intensityup to 2 days

Intensity of pain measured by numeric rating scale (NRS) 0-10

Secondary Outcome Measures
NameTimeMethod
Number of piritramid injection3 days

Piritramid 15 mg intramuscularly will be administered if numeric rating scale (NRS 0-10) of pain is NRS\>4

Side effects of treatment3 days

Incidence of stomach pain, heartburn, gas, diarrhea, constipation, nausea, vomiting, dizziness, others

Trial Locations

Locations (2)

Jiří Málek

🇨🇿

Praha 3, Czechia

Faculty Hospital Kralovske Vinohrady

🇨🇿

Praha, Czechia

© Copyright 2025. All Rights Reserved by MedPath